23 C
New York
Sunday, June 14, 2026

Tag: test

newssourceFORcompanyinformationcontent1marketreleases

Thea Energy Accelerates Fusion Energy with Helios Power Plant Digital Twin and AI Surrogate Models in Collaboration with NVIDIA, Synopsys, Argonne National Laboratory, and...

The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission

Titiminas Silver Commences Drill Program at the Madre Sierra Silver Mine, Peru

4,000-metre Packsack underground program underway concurrent with 15,500-metre HQ diamond drill programLIMA, Peru, June 8, 2026 /CNW/ - Titiminas Silver Inc. (TSXV: TITI) ("Titiminas"...

Behind CISCE with Jason: Inside a hardcore automobile manufacturer and its supplier network

BEIJING, June 8, 2026 /PRNewswire/ -- This is a report from China.org.cn Video Link: China International Supply Chain Expo, or CISCE, showcases not only...

Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions

SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 5, 2026, Calterah, a global leader in mmWave radar chips, unveiled its latest high-performance radar SoCs for...

Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions

SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 5, 2026, Calterah, a global leader in mmWave radar chips, unveiled its latest high-performance radar SoCs for...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Guild Wars 3, Modern Evolution of the MMORPG, Announced at Summer Game Fest for PC and PlayStation 5

The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 6, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight...

Guild Wars 3, Modern Evolution of the MMORPG, Announced at Summer Game Fest for PC and PlayStation 5

The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 5, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTest

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers